Guillain-Barré Syndrome: Clinical Presentation and Management
Clinical Presentation
- A patient with Guillain-Barré syndrome typically presents with tingling sensation in the extremities, ascending symmetric paralysis, and absent or reduced deep tendon reflexes 1, 2, 3
- Progressive, most often symmetrical muscle weakness with absent or reduced deep tendon reflexes is a common presentation 1, 4
- Often starts with sensory symptoms/neuropathic pain localized to lower back and thighs 1
- Tingling sensations (paresthesias) in the extremities are typically the initial symptoms 1, 2
- Weakness typically follows an ascending pattern (starting in lower extremities and progressing upward), though this is not universal 1, 3
- May involve facial, respiratory, bulbar, and oculomotor nerves 1, 2
- Dysregulation of autonomic nerves may occur, affecting blood pressure, heart rate, and bowel/bladder function 2, 3
Diagnostic Evaluation
- Neurologic consultation is essential for proper diagnosis 1
- MRI of spine with or without contrast to rule out compressive lesions 1
- Lumbar puncture typically shows elevated protein with normal or mildly elevated WBCs (albuminocytologic dissociation) 1, 3
- Serum antiganglioside antibody tests for GBS subtypes 1
- Electrodiagnostic studies to evaluate polyneuropathy 1, 2
- Pulmonary function testing to assess respiratory status 1, 5
Monitoring
- Regular assessment of respiratory function is critical as up to 30% of patients develop respiratory failure 5
- Use the "20/30/40 rule" to assess risk of respiratory failure: vital capacity <20 ml/kg, maximum inspiratory pressure <30 cmH₂O, or maximum expiratory pressure <40 cmH₂O 5, 6
- Monitor muscle strength in neck, arms, and legs using the Medical Research Council grading scale 5
- Assess swallowing and coughing difficulties to prevent aspiration 5, 6
- Monitor for autonomic dysfunction via ECG, heart rate, blood pressure, and bowel/bladder function 5, 6
Treatment
- Intravenous immunoglobulin (IVIg) at 0.4 g/kg/day for 5 days (total dose 2 g/kg) or plasmapheresis are the first-line treatments for GBS 1, 6
- Treatment should be initiated as early as possible in the disease course 6
- Corticosteroids alone are not recommended for GBS treatment as they have shown no significant benefit 6
- For immune checkpoint inhibitor-related GBS, a trial of corticosteroids may be reasonable (methylprednisolone 2-4 mg/kg/day) 1
Complications and Supportive Care
- Up to two-thirds of deaths in GBS occur during the recovery phase due to cardiovascular and respiratory dysfunction 5
- Common complications include pressure ulcers, hospital-acquired infections, and deep vein thrombosis 5, 6
- Pain, hallucinations, anxiety, and depression are frequent and require specific management 5, 6
- Multidisciplinary supportive care is crucial, including physiotherapy, occupational therapy, and speech therapy 5, 6